Rifaximin

利福昔明

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameRifaximin
Drug Alias NamerifaximinumRifaximinerifaximinaTargaxanXifaxanta +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA-directed RNA polymerase beta chain inhibitors
TargetsDNA-directed RNA polymerase beta chain
Therapy Area/IndicationsBone marrow transplant rejectionFunctional bowel disorderFear +[44] 
Global Approved IndicationsDiarrheaHyperammonemiaHepatic Encephalopathy +[4] 
Approved Indications in ChinaDiarrheaIrritable Bowel Syndrome
Original Approved Country/TerritoryN/A
Original Approved Date1985/01/01
Country/TerritoryBelgiumBulgariaCanada +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesAska Pharmaceutical Co LtdSalix PharmaceuticalsMansoura University +[11] 
Inactive CompaniesSalix Pharmaceuticals IncSandozUniversity Of California San Francisco +[18] 
Active IndicationsFunctional bowel disorderFearStress, Psychological +[20] 
Inactive IndicationsBone marrow transplant rejectionDyspepsiaAbdominal Pain +[24] 

Other Information

ATC CodeA07AA11D06AX11
Related LinksWikipediaDrugBankKEGG